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Angiogenesis, the formation of new blood capillaries from pre-existing vessels, is a physiological process essen-
tial for proper embryonic development, organ growth, and 
tissue repair.1 Blood vessels respond to a tightly regulated 
interplay of pro- and antiangiogenic factors to ensure proper 
vascular remodeling during development, wound healing, 
and pregnancy.1 Abnormal growth of blood vessels, caused 
by deregulation of this process, plays a critical role in the 
pathophysiology of several human diseases, including tumor 
growth and metastasis, proliferative retinopathies, age-related 
macular degeneration, neovascular glaucoma, ischemic dis-
orders, and rheumatoid arthritis.2 The proangiogenic factor 
vascular endothelial growth factor (VEGF) and its tyrosine-
kinase receptor, VEGF-R, have been identified as crucial 
regulators of both physiological and pathological angiogen-
esis.3 VEGF activates several intracellular signal transduction 
pathways that trigger the angiogenic process. Among them, 
the calcineurin/nuclear factor of activated T cells (NFAT) 
signaling axis has emerged as a critical mediator of VEGF-
stimulated angiogenesis.4–7
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Objective—Vascular endothelial growth factor (VEGF) has been identified as a crucial regulator of physiological and 
pathological angiogenesis. Among the intracellular signaling pathways triggered by VEGF, activation of the calcineurin/
nuclear factor of activated T cells (NFAT) signaling axis has emerged as a critical mediator of angiogenic processes. 
We and others previously reported a novel role for the plasma membrane calcium ATPase (PMCA) as an endogenous 
inhibitor of the calcineurin/NFAT pathway, via interaction with calcineurin, in cardiomyocytes and breast cancer cells. 
However, the functional significance of the PMCA/calcineurin interaction in endothelial pathophysiology has not been 
addressed thus far.
Approach and Results—Using in vitro and in vivo assays, we here demonstrate that the interaction between PMCA4 
and calcineurin in VEGF-stimulated endothelial cells leads to downregulation of the calcineurin/NFAT pathway and 
to a significant reduction in the subsequent expression of the NFAT-dependent, VEGF-activated, proangiogenic genes 
RCAN1.4 and Cox-2. PMCA4-dependent inhibition of calcineurin signaling translates into a reduction in endothelial cell 
motility and blood vessel formation that ultimately impairs in vivo angiogenesis by VEGF.
Conclusions—Given the importance of the calcineurin/NFAT pathway in the regulation of pathological angiogenesis, 
targeted modulation of PMCA4 functionality might open novel therapeutic avenues to promote or attenuate new vessel 
formation in diseases that occur with angiogenesis.  (Arterioscler Thromb Vasc Biol. 2014;34:2310-2320.)
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Calcineurin is a serine/threonine phosphatase activated in 
response to increments in the intracellular calcium concen-
tration.8 The best characterized substrate of calcineurin is the 
NFAT family of transcription factors.9 NFATs are synthesized 
as constitutively phosphorylated proteins that reside in the 
cytoplasm of the cell. In response to VEGF stimulation, calci-
neurin mediates dephosphorylation of NFATs, promoting their 
translocation into the nucleus.4,6,7 Once in the nucleus, acti-
vated NFATs trigger the expression of endothelial target genes 
that participate in the formation of new blood vessels.4–7 The 
relevance of calcineurin/NFAT signaling to the progression 
of pathological angiogenesis highlights the clinical potential 
of this route for the design of therapeutic interventions aimed 
at the treatment of neovascular-associated human diseases. 
Inhibition of calcineurin activity with the immunosuppressant 
drug cyclosporine A (CsA) has been shown to significantly 
decrease VEGF-mediated angiogenesis in animal models.5 
However, long-term treatments with CsA are associated with 
undesirable side effects in patients precluding its use to treat 
chronic diseases including diabetic retinopathies and cancer.10 
It is therefore essential to characterize endogenous cellular 
inhibitors of calcineurin that are less toxic and could be more 
suitable for chronic inhibition of this pathway. Toward this 
goal, we have identified recently a novel inhibitory interac-
tion between endogenous plasma membrane calcium ATPase 
(PMCA) proteins and calcineurin.11,12
PMCAs are high-affinity calcium pumps that extrude 
calcium from the cytosol to the extracellular medium.13 In 
humans, PMCA proteins are encoded by 4 independent genes 
termed PMCA1 to 4. PMCA1 and 4 are expressed ubiqui-
tously, whereas the expression of PMCA2 and 3 is restricted 
to specific cells and tissues.13 It is thought that PMCAs inhibit 
the activity of calcium-dependent calcineurin by tethering it 
to small low-calcium microdomains created by the calcium 
extrusion activity of the pump.14 We previously reported that 
PMCAs and calcineurin interact in endothelial cells15 although 
the functional significance of this interaction in endothelial 
pathophysiology has not been described thus far.
Nonstandard Abbreviations and Acronyms
CsA cyclosporine A
Erk1/2 extracellular signal–regulated kinases 1 and 2
HUVEC human umbilical vein endothelial cell
MLEC mouse lung endothelial cell
NFAT nuclear factor of activated T cells
PMA phorbol 12-myristate 13-acetate
PMCA plasma membrane calcium ATPase
VEGF vascular endothelial growth factor
Figure 1. Plasma membrane 
calcium ATPase 4 (PMCA4) 
downregulates the activity of 
the calcineurin/nuclear fac-
tor of activated T cells (NFAT) 
pathway in endothelial cells. 
A, Ectopic expression of human 
PMCA4 in human umbilical vein 
endothelial cells (HUVECs) by 
infection with adenovirus Ad-
PMCA4. Protein lysates from 
2.5×106 HUVECs infected with 
the indicated adenovirus (mul-
tiplicity of infection [MOI]=50) 
were immunoprecipitated with 
the anti–pan PMCA 5F10 mono-
clonal antibody. PMCA4 and 
PMCA1 proteins in the immu-
noprecipitated complexes were 
detected by Western blot using 
anti–PMCA4-specific (WB:α-
PMCA4) or anti–PMCA1-specific 
(WB:α-PMCA1) antibodies, 
respectively. The figure shows a 
representative experiment of 3 
performed. B, Ectopic expres-
sion of PMCA4 reduces the 
activity of the calcineurin/NFAT 
pathway. HUVECs (3×105) were 
coinfected with either Ad-LacZ 
or Ad-PMCA4 (MOI=50) for 24 hours, and then with Ad-NFAT-Luc (MOI=25) for an additional 24 hours. Infected cells were serum-starved 
in medium containing 0.5% fetal calf serum and left unstimulated (–) or treated with vascular endothelial growth factor (VEGF; 25 ng/mL) 
for 6 hours (VEGF). Mean±SE of 5 independent experiments are shown. *** indicates statistically significant differences (P≤0.005, accord-
ing to Student t test) when comparing VEGF-stimulated HUVEC infected with Ad-LacZ vs those infected with Ad-PMCA4. C, Absence 
of PMCA4 expression in mouse lung endothelial cells (MLECs) isolated from PMCA4 knockout mice. A total of 0.5 μg of total RNA, iso-
lated from MLECs obtained from PMCA4 wild-type (+/+) or knockout (−/−) mice, was retro-transcribed and the expression of the mouse 
PMCA4 and PMCA1 genes analyzed by semiquantitative polymerase chain reaction. Amplification of the housekeeping gene Hprt1 was 
used as a control. A figure representative of 3 independent experiments is shown. D, Targeted disruption of PMCA4 increases the activity 
of the calcineurin/NFAT pathway in MLECs. MLECs (3×105) isolated from PMCA4 wild-type (+/+) or knockout (−/−) animals were infected 
with Ad-NFAT-Luc (MOI=50) for 48 hours. After serum starvation in 0.5% fetal calf serum, cells were left unstimulated (–) or treated with 
VEGF (50 ng/mL) for 6 hours (VEGF) and luciferase activity was measured. Mean±SE of 5 independent experiments are shown. * indicates 
statistically significant differences (P≤0.05, according to Student t test) when comparing VEGF-stimulated PMCA4 (+/+) vs (−/−) MLECs.
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In this work, we demonstrate that the interaction between 
PMCA4 and calcineurin impairs endothelial cell motility and 
blood vessel formation in response to VEGF stimulation. An 
inhibitory effect of PMCA4 on VEGF-mediated activation of 
the calcineurin/NFAT signaling pathway, and the subsequent 
downregulation of RCAN1.4 and Cox-2 gene expression, is 
likely to account for angiogenesis inhibition.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
PMCA4 Negatively Regulates the Calcineurin/NFAT 
Pathway in VEGF-Activated Endothelial Cells
The role of PMCA as an inhibitor of the calcineurin/NFAT 
pathway in breast cancer cells12 and cardiomyocytes16 encour-
aged us to investigate whether this was also the case in VEGF-
activated endothelial cells.
We ectopically expressed human PMCA4 in human umbili-
cal vein endothelial cell (HUVEC) primary endothelial cells by 
Figure 2. Plasma membrane calcium ATPase 4 (PMCA4) negatively regulates the vascular endothelial growth factor (VEGF)–mediated 
upregulation of the proangiogenic protein RCAN1.4 in endothelial cells. A, Overexpression of human PMCA4 attenuates the VEGF-
induced upregulation of RCAN1.4 protein. Protein lysates obtained from human umbilical vein endothelial cell (HUVEC)–infected cells 
either unstimulated (–) or after stimulation with VEGF (25 ng/mL) for 4 hours (VEGF) were analyzed by Western blot with a rabbit anti-
DSCR1 antibody (α-RCAN1.4) to determine RCAN1.4 expression. Histograms show data as mean±SE of 5 independent experiments. *** 
indicates statistically significant differences (P≤0.005, according to Student t test) when comparing VEGF-stimulated cells infected with 
adenovirus Ad-LacZ vs Ad-PMCA4. B, PMCA4 overexpression reduces RCAN1.4 gene expression. Infected HUVECs were left unstimu-
lated (–) or stimulated with VEGF (25 ng/mL) for 2 hours. RNA levels for RCAN1.4 were determined by quantitative reverse transcription 
polymerase chain reaction (PCR) using the 2–ΔΔCT method. Mean±SE of 6 independent experiments is shown. ** indicates statistically 
significant differences (P≤0.01, according to Student t test) when comparing VEGF-stimulated cells infected with Ad-LacZ vs Ad-PMCA4. 
C, Small interfering RNA (siRNA) mediated specific knockdown of PMCA4 in HUVECs. Protein expression of PMCA1 and 4 proteins in 
HUVECs transfected with a nontargeting control siRNA (si-NT) or a siRNA specific for human PMCA4 (si-PMCA4) was determined by 
Western blot. Images are representative of 3 independent experiments. Histograms represent RNA levels for PMCA4 and PMCA1 in the 
transfected cells determined by qRT-PCR. Mean±SE of 9 independent experiments is shown. *** indicates statistically significant differ-
ences (P≤0.005, according to Student t test) in PMCA4 RNA expression when comparing cells transfected with si-NT vs si-PMCA4.  
D, PMCA4 silencing upregulates the expression of RCAN1.4. Western blot analyses of RCAN1.4 expression (α-RCAN1.4) in protein 
lysates of HUVECs transfected with a PMCA4-specific siRNA (si-PMCA4) or a nontargeting, control siRNA (si-NT). Cells were stimulated 
with VEGF (25 ng/mL) for 4 hours where indicated. Histograms show mean±SE of RCAN1.4 protein expression calculated from 3 inde-
pendent experiments. * indicates statistically significant differences (P≤0.05, according to Student t test) when comparing HUVEC cells 
transfected with si-NT vs si-PMCA4. # indicates statistically significant differences (P≤0.05, according to Student t test) when comparing 
VEGF-stimulated HUVEC cells transfected with si-NT vs si-PMCA4. E, Targeted disruption of PMCA4 increases RCAN1.4 protein expres-
sion. Western blot analysis of RCAN1.4 expression (α-RCAN1.4) in mouse lung endothelial cells (MLECs) isolated from PMCA4 wild-type 
(+/+) or knockout (−/−) mice. Where indicated, MLECs were stimulated with VEGF (50 ng/mL) for 4 hours. Histogram shows mean±SE of 
3 independent experiments performed with 3 different batches of MLEC cells obtained from independent isolations. *** indicates statisti-
cally significant differences (P≤0.005, according to Student t test) when comparing RCAN1.4 protein expression in PMCA4 wild-type vs 
knockout MLEC. ## indicates statistically significant differences (P≤0.01, according to Student t test) when comparing VEGF-stimulated 
PMCA4 wild-type vs knockout MLEC. A to E, In Western blot assays the expression of tubulin was analyzed using a mouse monoclonal 
antitubulin antibody (α-Tubulin) as loading control.
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infection with adenovirus Ad-PMCA4 (Figure 1A). To quan-
tify the activity of the calcineurin/NFAT pathway, cells were 
also infected with a luciferase-based, NFAT-dependent adeno-
viral reporter vector (Ad-NFAT-Luc). Ectopic expression of 
PMCA4 significantly decreased (31.9% reduction, compared 
with cells infected with control Ad-LacZ) the VEGF-induced 
activation of the luciferase reporter (Figure 1B). Equivalent 
results were observed when the calcineurin/NFAT pathway 
was activated by stimulating the infected cells with phorbol 
12-myristate 13-acetate (PMA) and the calcium ionophore 
A23187 (Figure IA in the online-only Data Supplement).
To substantiate this observation, we analyzed the activity of 
the calcineurin/NFAT pathway in mouse lung endothelial cells 
(MLECs) isolated from PMCA4 knockout mice or from their 
corresponding wild-type littermates (Figure 1C). MLECs were 
infected with Ad-NFAT-Luc, and the calcineurin/NFAT path-
way was activated by stimulation with VEGF (Figure 1D) or 
PMA+Io (Figure IB in the online-only Data Supplement). In 
both cases, determination of luciferase activity in the infected 
cells revealed increased activation of the calcineurin/NFAT 
pathway in PMCA4-deficient cells compared with equivalent 
wild-type cells.
These results demonstrate that PMCA4 plays a substantial 
role as an endogenous inhibitor of the calcineurin/NFAT sig-
nal transduction pathway in activated endothelial cells.
PMCA4 Inhibits the Expression of NFAT-
Dependent, Proangiogenic Genes in 
VEGF-Stimulated Endothelial Cells
Stimulation of endothelial cells with VEGF has been reported 
to activate the expression of NFAT-target genes, including 
RCAN1.4 and Cox-2, whose products actively participate in 
the onset of angiogenesis.5–7,17–19 The inhibitory effect pro-
duced by PMCA4 on the VEGF-induced activity of the cal-
cineurin/NFAT pathway in endothelial cells prompted us to 
next examine the role of PMCA4 as a negative regulator of 
angiogenesis gene expression.
Ectopic expression of PMCA4 in HUVECs by infection with 
Ad-PMCA4 markedly inhibited the VEGF-dependent upregu-
lation of RCAN1.4, both at the level of protein (Figure 2A) 
and mRNA (Figure 2B) expression (48.4% and 24.8% reduc-
tion, respectively). Similarly, VEGF-mediated upregulation of 
Cox-2 protein and mRNA was also diminished (52.1% and 
29.4% reduction, respectively) by PMCA4 overexpression 
(Figure IIA and IIB in the online-only Data Supplement). In 
contrast, expression of Cox-1, which is not regulated by the 
calcineurin/NFAT pathway, remained unchanged in PMCA4-
overexpressing cells (Figure IIA in the online-only Data 
Supplement), highlighting the role of PMCA4 as a regulator 
of NFAT-driven genes.
To corroborate these findings, we next measured angio-
genesis gene expression in endothelial cells in the absence of 
PMCA4. Transfection of HUVEC cells with a small interfer-
ing RNA pool directed to PMCA4 robustly silenced the expres-
sion of endogenous PMCA4 at the protein and mRNA level, 
without affecting PMCA1 expression (Figure 2C). PMCA4 
silencing increased the expression of RCAN1.4 in both rest-
ing and VEGF-stimulated cells (1.9- and 3.86-fold increase, 
respectively, compared with a nontargeting small interfering 
RNA pool; Figure 2D). Similarly, small interfering RNA–
mediated suppression of PMCA4 in HUVEC cells signifi-
cantly increased the expression of the proangiogenic protein 
Cox-2 in VEGF-stimulated cells (Figure IIIA in the online-
only Data Supplement). Consistent with these results, analysis 
Figure 3. Plasma membrane calcium 
ATPase 4 (PMCA4) inhibits endothelial 
cell migration. A, Overexpression of 
PMCA4 significantly reduces endothelial 
cell migration. Representative images 
of wound-healing migration assays 
performed with human umbilical vein 
endothelial cells infected with adenovirus 
Ad-PMCA4 or Ad-LacZ at multiplicity of 
infection=50. Mean±SE of 6 independent 
experiments is shown. * indicates sta-
tistically significant differences (P≤0.05, 
according to Student t test) when com-
paring the migration of cells infected with 
Ad-LacZ vs Ad-PMCA4. B, Targeted 
disruption of PMCA4 increases endothelial 
cell migration. Representative images of 
wound-healing assays performed with 
MLECs isolated from wild-type (+/+) or 
PMCA4 knockout animals (−/−). Histogram 
shows mean±SE of 4 independent experi-
ments. ** indicates statistically significant 
differences (P≤0.01, according to Student 
t test) when comparing the migration of 
PMCA4 wild-type vs PMCA4 knockout 
MLECs. In both cases (A and B) images 
were taken at time zero and after incuba-
tion for 24 hours in the corresponding 
complete medium supplemented with 
vascular endothelial growth factor. The 
migrated area was calculated by subtracting the value of the nonmigrated area to the area of the wound at time zero. The migrated area 
is expressed as a percentage of the total area at time zero.
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of PMCA4–/– MLECs revealed higher levels of RCAN1.4 and 
Cox-2 protein, both in resting and VEGF-treated conditions, 
than those found in equivalent wild-type cells (Figure 2E; 
Figure IIIB in the online-only Data Supplement).
Taken together, these data indicate that inhibition of calci-
neurin/NFAT signaling by PMCA4 results in a downregula-
tion of VEGF-induced RCAN1.4 and Cox-2 gene expression.
PMCA4 Reduces Endothelial Cell Migration and 
Blood Vessel Formation but Not Cell Proliferation
Blockage of the calcineurin/NFAT pathway by pharmacolog-
ical doses of CsA has been shown to abrogate VEGF-driven 
endothelial cell migration, but not endothelial prolifera-
tion.5 We thus performed wound-healing migration assays 
with cells overexpressing or lacking PMCA4 to investi-
gate whether PMCA4 might play a role in the regulation of 
endothelial cell migration. Notably, Ad-PMCA4–infected 
HUVECs had a reduced ability to migrate into the wound 
compared with control-infected cells (39.8% reduction; 
Figure 3A). Conversely, PMCA4–/– MLECs displayed sig-
nificantly increased cellular motility (66.6% increment over 
equivalent wild-type cells; Figure 3B). These results imply 
that PMCA4 plays a negative role in the regulation of endo-
thelial cell migration.
As VEGF-induced endothelial cell proliferation is an addi-
tional essential step in the progression of angiogenesis, we 
next evaluated whether PMCA4 participates in the regulation 
of this process. No significant differences in proliferation were 
found between PMCA4-expressing cells and control Ad-LacZ–
infected cells (Figure 4A). Because VEGF-dependent pro-
liferation of endothelial cells requires activation of the 
mitogen-activated protein kinase kinase (MEK)-extracellular 
signal–regulated kinases 1 and 2 (Erk) signaling pathway,20 
we also tested whether PMCA4 modulates activation of Erk 
in HUVECs. Results showed that VEGF stimulation increased 
phosphorylation (activation) of Erk1/2 proteins to a similar 
extent in cells overexpressing either PMCA4b or β-galactosidase 
(Figure 4B). Consistent with this finding, HUVECs silenced 
for PMCA4 expression displayed similar levels of Erk1/2 phos-
phorylation to control (nontargeting small interfering RNA 
pool) cells after VEGF stimulation (Figure 4C). Taken together, 
these results indicate that PMCA4 does not participate in the 
regulation of endothelial cell proliferation.
Given that PMCA4 controls endothelial cell migration, we 
next addressed whether PMCA4 participates in the regula-
tion of endothelial tube formation. Compared with control-
infected cells, basal tubular morphogenesis in an in vitro 
Matrigel assay was reduced significantly (34%) in HUVECs 
Figure 4. Plasma membrane calcium 
ATPase 4 (PMCA4) does not regulate 
endothelial cell proliferation. A, Human 
umbilical vein endothelial cells (HUVECs; 
2×103) infected with adenovirus Ad-
PMCA4 or Ad-LacZ were plated on 
96-well plates. The number of viable cells 
was determined by MTT (3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) after overnight incubation (t=0) 
and after 3 and 6 days of incubation in 
complete endothelial cell growth medium 
supplemented with vascular endothelial 
growth factor (VEGF; 25 ng/mL). Histo-
grams represent mean±SE of 6 indepen-
dent experiments. B and C, Western blot 
analysis of the phosphorylation (activa-
tion) status of Erk1/2 proteins using an 
anti–phospho-extracellular signal-regu-
lated kinases 1 and 2 (Erk1/2)-specific 
antibody (α-PhosphoErk1/2) in HUVECs 
overexpressing (Ad-PMCA4) or deficient 
(si-PMCA4) in PMCA4 expression. Cells 
were stimulated with VEGF (25 ng/mL) for 
5 minutes where indicated. Histograms 
represent quantification of Erk1/2 phos-
phorylation with respect to the levels of 
total Erk1/2 in PMCA4-overexpressing 
(B) or PMCA4-deficient (C) cells, com-
pared with the values observed in the 
corresponding control cells infected with 
Ad-LacZ or transfected with nontarget-
ing control small interfering RNA (si-NT), 
respectively. Histograms show mean±SE 
of ≥3 independent experiments.
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Figure 5. Plasma membrane calcium ATPase 4 (PMCA4) attenuates vascular endothelial growth factor (VEGF)–induced angiogenesis.  
A, PMCA4 overexpression in endothelial cells blocks in vitro tube formation in response to VEGF stimulation. Human umbilical vein endo-
thelial cells (HUVECs) infected with adenovirus as indicated were plated on a layer of Growth-Factor Reduced Matrix (Geltrex) in Medium 
200 containing 2% fetal calf serum, and where indicated VEGF (25 ng/mL), and incubated for 24 hours. Images show representative 
fields from experiments quantified in the histogram. Histogram represents mean±SE of 5 independent experiments. * indicates statisti-
cally significant differences (P≤0.05, according to Student t test) when comparing tube formation in VEGF-stimulated cells infected with 
Ad-LacZ vs those infected with Ad-PMCA4. B, PMCA4 overexpression attenuates in vivo tube formation. A mixture of Growth-Factor 
Reduced Matrigel (BD Bioscience) containing VEGF (500 ng/mL), heparin (376 μg/mL), and 2×109 plaque-forming units of the correspond-
ing adenovirus was implanted subcutaneously in mice, and 7 days later implants were collected and analyzed. Hemoglobin (Hb) content 
was measured spectrophotometrically. The number of blood vessels in each implant was determined in hematoxylin-eosin (H&E)–stained 
sections of the plug. Histogram of Hb content shows mean±SE of 3 independent experiments with ≥7 animals per group in each experi-
ment. Pictures show representative fields of H&E-stained sections of plugs. The number of vessel containing blood cells per field (magni-
fication ×20) was quantified in 10 random fields per sample. Histogram depicting number of blood vessels represents mean±SE of values 
calculated from 8 different plugs per group, obtained from 3 independent experiments. * and # indicate statistically significant differences 
(P≤0.05, according to Student t test) in Hb content and number of blood vessels, respectively, when comparing Matrigel plugs contain-
ing Ad-LacZ vs those containing Ad-PMCA4. C, Knockdown of PMCA4 expression increases the angiogenic ability of endothelial cells. 
Matrigel in vitro tube formation assays of HUVECs transfected with a small interfering RNA (siRNA) specific for PMCA4 (si-PMCA4) or 
with control nontargeting siRNA (si-NT) were performed as described in A. Images show representative fields from experiments quantified 
in the histogram. Histogram represent mean±SE of 7 independent experiments. * and # indicate statistically significant differences in tube 
formation (P≤0.05, according to Student t test) in cells transfected with si-NT or si-PMCA4, respectively, when comparing nontreated vs 
VEGF-stimulated cells. && and †† indicate statistically significant differences in tube formation (P≤0.01, according to Student t test) in 
resting or VEGF-stimulated HUVEC cells, respectively, when comparing cells transfected with si-NT vs those transfected with si-PMCA4. 
D, Targeted disruption of PMCA4 enhances endothelial tube formation in vivo. Matrigel assays were as in B only that no adenovirus was 
included in the Matrigel mixture and the plugs were implanted in 4-week-old PMCA4 wild-type (+/+) or knockout (−/−) mice. (Continued  )  
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overexpressing PMCA4 (Figure 5A). Moreover, the additional 
VEGF-mediated tube formation was also clearly reduced by 
PMCA4 overexpression (Figure 5A), suggesting that PMCA4 
negatively regulates endothelial tube formation. To validate 
this observation in a more physiological setting, we performed 
in vivo angiogenesis assays in mice by subcutaneous injec-
tion of a mixture of low growth-factor Matrigel, VEGF, and 
an adenoviral vector (either Ad-PMCA4 or control Ad-Lacz). 
Consistent with our in vitro findings, Matrigel plugs contain-
ing Ad-PMCA4 produced fewer vessels (58.2% reduction) 
and had lower hemoglobin content (47.1% decrease) than 
control implants (Figure 5B), indicating that ectopic expres-
sion of PMCA4 impairs the angiogenic capability of endothe-
lial cells in vivo.
To verify that our observations were not merely an effect 
of PMCA4 overexpression, we next assessed the involve-
ment of endogenous PMCA4 in the regulation of angio-
genesis. Knockdown of PMCA4 expression significantly 
increased HUVEC tubular morphogenesis, in both basal and 
VEGF-stimulated conditions (23.07% and 22.05% increase, 
respectively, compared with tube formation of control cells; 
Figure 5C). Furthermore, vascularization and hemoglobin 
content of Matrigel plugs injected into PMCA4–/– mice was 
increased 3.1- and 2.3-fold, respectively, compared with 
plugs implanted in wild-type littermates (Figure 5D). Thus, 
these data strongly support a negative role for endogenous 
PMCA4 in blood vessel formation. To further reassure the 
in vivo significance of these observations, we evaluated the 
role of PMCA4 in blood vessel formation using the mouse 
hindlimb ischemia model of pathological angiogenesis. We 
induced unilateral ischemia by femoral artery ligation in 
the lower limb of PMCA4 wild-type or knockout animals 
and examined blood flow perfusion of the ischemic limb by 
laser Doppler perfusion imaging, at 5 and 14 days after sur-
gery. Postischemic perfusion at both times was significantly 
higher in the ischemic limbs of PMCA4 knockout animals 
than in those of their wild-type littermates, suggesting that 
lack of PMCA4 results in a stronger postischemic revascu-
larization (Figure 6). No significant differences in blood flow 
were detected between the nonischemic contralateral limb of 
PMCA4 (+/+) and (−/−) animals.
Altogether, these results demonstrate a novel role for 
PMCA4 as a negative regulator of angiogenesis in vivo and 
suggest the involvement of PMCA4 in the onset of vascular 
pathologies that occur with angiogenesis.
Interaction Between PMCA4 and 
Calcineurin Is Essential for PMCA-
Mediated Inhibition of Angiogenesis
We previously reported that PMCA4 exerts its negative effects 
on the calcineurin/NFAT pathway via interaction with calci-
neurin A.11 Indeed, disruption of the interaction between 
endogenous PMCA and calcineurin, by overexpression of 
the PMCA-interacting domain, strongly increases the activ-
ity of the calcineurin/NFAT pathway in breast cancer cells.21 
Therefore, we next assessed whether the PMCA4-mediated 
negative effect on angiogenesis required interaction between 
PMCA4 and calcineurin.
For this purpose, we disrupted the interaction between 
endogenous PMCA4 and calcineurin in HUVECs by infection 
with adenovirus Ad-ID4 that encodes a Flag-tagged region of 
PMCA4 encompassing amino acids 428 to 651, correspond-
ing to the domain implicated in the interaction with calcineu-
rin11 (Figure IVA in the online-only Data Supplement). Plasma 
membrane–associated proteins were extracted from infected 
cells using a ProteoExtract Subcellular Proteome Extraction 
Kit, and the levels of calcineurin were analyzed by Western blot 
using a monoclonal anticalcineurin antibody. Overexpression 
of Flag-PMCA4(428–651) resulted in a significant decrease in 
the levels of calcineurin associated with the plasma membrane 
(Figure IVA in the online-only Data Supplement), suggesting 
that Flag-PMCA4(428–651) was competing with endogenous 
PMCA4 for binding to calcineurin and, therefore, disrupting 
the interaction between endogenous PMCA4 and calcineurin. 
PMCA4 expression in the membrane did not change signifi-
cantly by infection with Ad-ID4, indicating that the decrease 
in membrane-associated calcineurin was not a consequence 
of a reduction in PMCA4 plasma membrane levels after cell 
infection with Ad-ID4 (Figure IVA in the online-only Data 
Supplement).
To discard the possibility that the changes observed in the 
levels of membrane-associated calcineurin were attributable 
to downregulation of calcineurin expression in Ad-ID4–
infected cells, calcineurin total levels were determined by 
Western blot in proteins from whole-cell lysates. Total levels 
of calcineurin were equivalent in cells infected with Ad-LacZ 
or Ad-ID4 (Figure IVA in the online-only Data Supplement). 
Likewise, Western blot analysis of PMCA4 levels in whole-
cell lysates did not show any significant changes in control 
or Ad-ID4–infected cells (Figure IVA in the online-only Data 
Supplement).
To quantify the activity of the calcineurin/NFAT pathway 
in Ad-ID4–transduced HUVECs, cells were further infected 
with Ad-NFAT-Luc. Measurement of luciferase activity after 
stimulation of transduced HUVEC with VEGF revealed 
that Flag-PMCA4(428–651) expression induced a 2.01-fold 
increase in reporter activity (Figure 7A).
Consistent with the results observed in PMCA4 knock-
out MLECs, disruption of the PMCA4/calcineurin interac-
tion by expression of Flag-PMCA4(428–651) in HUVEC 
cells resulted in an increase in the basal (Figure V in the 
online-only Data Supplement) and VEGF-induced expres-
sion of RCAN1.4 (Figure 7B). To confirm that the increase 
in RCAN1.4 expression was a consequence of increased 
calcineurin activity, through disruption of its interaction 
with PMCA4, we repeated this assay after preincubation of 
Figure 5. Continued Determination of hemoglobin content and number of blood vessels was as in B. Histogram of Hb content shows 
mean±SE of ≥9 different plugs per group, obtained from 3 independent experiments. Images show representative fields of H&E-stained 
sections of plugs. Histogram depicting number of blood vessels represents mean±SE of values calculated from ≥5 plugs per group 
obtained from 3 independent experiments. * and # indicate statistically significant differences (P≤0.05, according to Student t test) in Hb 
content and number of blood vessels respectively, when comparing assays performed in PMCA4 wild-type vs knockout mice.
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HUVECs with the calcineurin-inhibitor CsA before VEGF 
stimulation. As anticipated, CsA pretreatment abrogated not 
only the VEGF-mediated upregulation of RCAN1.4 expres-
sion but also the additional increase promoted by Flag-
PMCA4(428–651) (Figure IVB in the online-only Data 
Supplement). Collectively, these data indicate that disruption 
of the PMCA4/calcineurin interaction in endothelial cells 
eliminates the inhibitory effect of PMCA4, leading to an 
increase in the activity of the calcineurin/NFAT pathway.
We have shown that overexpression of PMCA4 in HUVECs 
significantly attenuates RCAN1.4 expression in response 
to VEGF stimulation (Figure 2A). To further consider the 
importance of an intact PMCA4/calcineurin interaction for 
inhibition of angiogenesis by PMCA4, we examined whether 
overexpression of PMCA4 could downregulate RCAN1.4 
expression under conditions that impaired this interaction. 
Thus, HUVECs were transduced with both Ad-PMCA4 and 
Ad-ID4, and RCAN1.4 expression was assessed by Western 
blot. As expected, disruption of the PMCA4/calcineurin inter-
action, through overexpression of Flag-PMCA4(428–651), 
abolished the PMCA4-induced reduction in RCAN1.4 expres-
sion (Figure 7C), indicating that this interaction is essential 
for PMCA4-induced inhibition of NFAT-dependent, angio-
genic gene expression. In agreement with our previous results 
illustrating that PMCA4 is not involved in the regulation of the 
MEK-Erk1/2 pathway (Figure 4), disruption of the PMCA4/
calcineurin interaction in HUVECs by infection with Ad-ID4 
did not alter the activation (phosphorylation) of endothelial 
Erk1/2 proteins in response to VEGF stimulation (Figure 7D).
Finally, we evaluated the significance of the PMCA4/
calcineurin interaction in endothelial cell migration and for-
mation of capillary-like structures. In concurrence with our 
results in PMCA4 knockout MLEC (Figure 3B), disruption 
of the PMCA4/calcineurin interaction by overexpression of 
Flag-PMCA4(428–651) augmented endothelial cell motil-
ity (Figure 7E). Interestingly, ectopic expression of Flag-
PMCA4(428–651) significantly increased tube formation in 
Matrigel assays (even in the absence of VEGF stimulation; 
Figure 7F) to a degree similar to that previously observed in 
cells stimulated with VEGF (Figure 5A and 5C). This suggests 
that enhancement of angiogenesis by blockage of the interac-
tion between PMCA4 and calcineurin might have important 
therapeutic applications.
Altogether, these data demonstrate that disruption of the 
PMCA4/calcineurin interaction enhances significantly the 
activity of the calcineurin/NFAT pathway and consequently the 
expression of NFAT-dependent, proangiogenic genes, result-
ing in a significant increase in endothelial cell angiogenesis.
We have reported previously an inhibitory interaction 
between PMCA4 and endothelial nitric oxide synthase that 
results in downregulation of nitric oxide production by endo-
thelial cells.15 PMCA4 also interacts with endothelial nitric 
oxide synthase through the region 428 to 651, so overexpres-
sion of Flag-PMCA4(428–651) might also disrupt the interac-
tion between PMCA4 and endothelial nitric oxide synthase, 
leading to endothelial nitric oxide synthase activation and an 
increase in nitric oxide production. It is well established that 
nitric oxide promotes angiogenesis.22 Therefore, although our 
experiments demonstrate the involvement of the calcineurin/
NFAT pathway in the angiogenic increase elicited by Flag-
PMCA4(428–651), we cannot rule out that overexpression 
of this region of PMCA4 may be activating alternative pro-
angiogenic signaling pathways that contribute as well to the 
observed increase in angiogenesis.
Discussion
In this work, we show that PMCA4 inhibits the activation 
of the calcineurin/NFAT pathway on VEGF stimulation 
of endothelial cells, leading to a significant attenuation of 
VEGF-mediated angiogenesis. Consistent with these findings, 
PMCA4 has also been shown to play a negative role in the 
progression of cardiac hypertrophy via downregulation of cal-
cineurin signaling in cardiomyocytes.16
It is hypothesized that PMCA negatively regulates the activ-
ity of calcineurin by recruiting the phosphatase to low-calcium 
microdomains created by the calcium extrusion ability of the 
pump.14 In support of this hypothesis we demonstrate here that 
the interaction between PMCA4 and calcineurin is essential 
for the negative effect exerted by PMCA4 on VEGF-induced 
signaling.
An interaction between calcineurin and calcium influx 
channels is thought to place the phosphatase into local high-
calcium subcellular microdomains that promote activation of 
calcineurin/NFAT signaling.23–26 Here, we show that an inter-
action between calcineurin and the PMCA4 calcium extru-
sion pump downregulates calcineurin/NFAT activity. It is 
Figure 6. Plasma membrane calcium 
ATPase 4 (PMCA4) gene ablation 
enhances postischemic hindlimb per-
fusion. Representative laser Doppler 
images showing blood flow at 5 and  
14 days after surgery, in sham-operated 
nonischemic legs (S) and femoral-ligated 
ischemic legs (I) of PMCA4 knockout 
(PMCA4 (−/−)) or wild-type (PMCA4 (+/+)) 
mice. Histogram represents mean±SE 
(n≥8) of blood flow quantification at 5 and 
14 days post surgery calculated as ratio 
of blood flow in ischemic to contralateral 
foot. ** and # indicate statistically sig-
nificant differences P≤0.01 and P≤0.05, 
respectively (according to Student t test) 
in foot perfusion when comparing PMCA4 
wild-type vs knockout animals.
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therefore tempting to speculate that regulation of calcineurin 
might involve shuttling between high- and low-calcium sub-
cellular microdomains via interaction with calcium transport-
ers responsible for influx or efflux of calcium. In accord with 
this notion, activation of the calcineurin/NFAT pathway in 
cardiomyocytes has been shown to require a calcium signaling 
microdomain generated by calcium influx from a small frac-
tion of L-type calcium channels specifically housed in caveo-
lae.27 PMCA4 expression has been localized to lipid rafts 
and caveolae in endothelial,28 cardiac,29 and vascular smooth 
Figure 7. Plasma membrane calcium ATPase 4 PMCA4 downregulates nuclear factor of activated T cells (NFAT)–dependent proangio-
genic events via interaction with calcineurin. A, Disruption of the PMCA4/calcineurin interaction increases the activity of the calcineurin/
NFAT pathway in vascular endothelial growth factor (VEGF)–stimulated endothelial cells. Human umbilical vein endothelial cells (HUVECs) 
were infected with adenovirus Ad-LacZ or Ad-ID4 (multiplicity of infection [MOI]=150) for 24 hours and subsequently with Ad-NFAT-Luc 
(MOI=25) for a further 24 hours. After serum starvation in endothelial cell growth medium (0.5% fetal calf serum), cells were stimulated 
with VEGF (25 ng/mL) for 6 hours. Induction of the luciferase activity of the reporter vector in cells infected with Ad-LacZ was taken as 
a reference (100%). Histograms show data as mean±SE of 3 independent experiments. ** indicates statistically significant differences 
(P≤0.01, according to Student t test) when comparing the percentage of NFAT activation in VEGF-stimulated cells infected with Ad-
LacZ vs those infected with Ad-ID4. B, Disruption of the PMCA4/calcineurin interaction in endothelial cells enhances the expression 
of RCAN1.4 in response to VEGF. Western blot analysis of protein lysates obtained from 3×105 HUVECs infected with the indicated 
adenovirus (MOI=150) for 72 hours. Where indicated, cells were stimulated with VEGF (25 ng/mL) for 4 hours. Protein levels of RCAN1.4 
were determined by Western blot with a rabbit anti-DSCR1 antibody (α-RCAN1.4). Histograms show data as mean±SE of 5 independent 
experiments. *** indicates statistically significant differences (P≤0.005, according to Student t test) when comparing RCAN1.4 protein 
expression in VEGF-stimulated cells infected with Ad-LacZ vs those infected with Ad-ID4. C, Impairment of the PMCA4/calcineurin inter-
action abolishes PMCA4-mediated downregulation of RCAN1.4 expression. HUVECs were coinfected with Ad-PMCA4 (MOI=50) and 
either Ad-LacZ (MOI=150) or Ad-ID4 (MOI=150). Control cells were infected with Ad-LacZ (MOI=200). Cells were stimulated with VEGF 
(25 ng/mL) for 4 hours where indicated and protein expression of RCAN1.4 was analyzed by Western blot as described in B. Histograms 
show data as mean±SE of 4 independent experiments. ** indicates statistically significant differences (P≤0.01, according to Student t test) 
in RCAN1.4 protein expression in VEGF-stimulated cells when comparing cells infected with Ad-LacZ vs those infected with Ad-PMCA4. 
# and & indicate statistically significant differences (P≤0.05, according to Student t test) when comparing VEGF-stimulated cells infected 
with Ad-LacZ vs Ad-ID4 (#) or with Ad-Laz+Ad-PMCA4 vs Ad-PMCA4+Ad-ID4 (&). D, VEGF-induced activation of extracellular signal–
regulated kinase (Erk) signaling is not altered by disruption of the PMCA4/calcineurin interaction. Western blot analysis of protein lysates 
obtained from 3×105 HUVECs infected with the indicated adenovirus (MOI=150) for 72 hours. Where indicated, cells were stimulated with 
VEGF (25 ng/mL) for 5 minutes. Phosphorylation (activation) status of Erk1/2 proteins was determined using an anti–phospho-Erk1/2-spe-
cific antibody (α-PhosphoErk1/2). Histogram represents quantification of Erk1/2 phosphorylation with respect to the levels of total Erk1/2. 
E, Disruption of the PMCA4/calcineurin interaction enhances the motility of HUVEC cells. HUVEC cells were infected with Ad-LacZ or 
Ad-ID4 (MOI=150) for 72 hours. Migration analysis of infected cells was performed as described in Materials and Methods. Histograms 
show data as mean±SE of 7 independent experiments. *** indicates statistically significant differences (P≤0.005, according to Student 
t test) when comparing migration in cells infected with Ad-LacZ vs those infected with Ad-ID4. F, Disruption of the PMCA4/calcineurin 
interaction augments endothelial cell tube formation. HUVECs were infected with Ad-LacZ or Ad-ID4 (MOI=150) for 72 hours. Tubular 
morphogenesis was analyzed by plating infected cells onto a layer of Growth-Factor Reduced Matrix (Geltrex) in Medium 200 containing 
2% fetal calf serum, for 24 hours. Images show representative fields from experiments quantified in the histogram. Histograms show data 
as mean±SE of 8 independent experiments. *** indicates statistically significant differences in tube formation (P≤0.005, according to Stu-
dent t test) when comparing cells infected with Ad-LacZ vs those infected with Ad-ID4. B to D, In Western blot assays the expression of 
tubulin was analyzed using a mouse monoclonal antitubulin antibody (α-Tubulin) as loading control.
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muscle cells30 and, interestingly, the calcium-removal function 
of PMCA4 is impaired in smooth muscle cells of a caveolin-1 
knockout mouse.30 Whether targeting of PMCA4 to caveolae 
is necessary to downregulate VEGF-induced signaling of the 
calcineurin/NFAT pathway requires further investigation.
Our data also reveal that PMCA4-mediated inhibition of 
calcineurin signaling in endothelial cells leads to downregula-
tion of RCAN1.4 and Cox-2 expression, together with an atten-
uation of VEGF-activated, proangiogenic cellular processes 
including migration and tubular morphogenesis. Although our 
results do not directly demonstrate that reduction of these cel-
lular functions is linked to PMCA4-mediated downregulation 
of RCAN1.4 and Cox-2, both proteins have been described to 
promote endothelial cell migration and tube formation,17,18,31 
suggesting that they likely play a significant role in the 
PMCA4-directed inhibition of angiogenesis. In agreement 
with this idea, PMCA4-deficient MLECs presented higher 
expression of Cox-2 (Figure IIIB in the online-only Data 
Supplement) and enhanced cellular migration (Figure 3B) than 
wild-type counterparts. However, specific inhibition of Cox-2 
functionality by incubation of PMCA4(−/−) MLECs with 
the Cox-2 selective inhibitor Etoricoxib resulted in a strong 
reduction in cell motility (Figure VI in the online-only Data 
Supplement), indicating that elevated expression of Cox-2 in 
PMCA4 knockout cells is linked to their enhanced motility.
The results of our gain- or loss-of-PMCA4 function 
experiments might be particularly relevant in the context of 
pathophysiological processes associated with changes in the 
expression of PMCA proteins. Initial investigations in our lab-
oratory have revealed that stimulation of HUVEC cells with 
VEGF induces a transient upregulation of PMCA4 protein 
levels that peaks at 4 to 6 hours after VEGF treatment (Figure 
VII in the online-only Data Supplement). PMCA4 expression 
has been reported to increase in the late phase of osteoclast 
differentiation.32 Interestingly, PMCA4 upregulation in the 
differentiating osteoclast is dependent on the calcium-trig-
gered activation of the calcineurin/NFAT pathway. In turn, 
increased osteoclast expression of PMCA4 leads to cytoplas-
mic calcium removal, creating a negative feedback regulatory 
loop.32 Our results suggest that VEGF-induced upregulation 
of PMCA4 might also be functioning as a negative feedback 
mechanism to regulate the activation of the calcineurin/NFAT 
pathway in endothelial cells. Whether VEGF-induced upregu-
lation of PMCA4 in endothelial cells is mediated by NFAT-
dependent transcriptional activation of the PMCA4 gene 
promoter deserves additional investigation.
Further supporting the functional significance of changes in 
the expression of PMCA4 in cardiovascular pathophysiology, 
Ewart et al33 recently reported that PMCA levels increase in 
mouse aortic tissue during atherosclerosis.
In this work, we demonstrate that PMCA4 modulates 
RCAN1.4 expression in endothelial cells through regulation 
of the calcineurin/NFAT pathway. Interestingly, calcineurin-
dependent expression of RCAN1.4 in other cell types has been 
linked to pathological vascular wall remodeling34 and athero-
sclerosis progression.35 Hence, the potential role of PMCA4 
in the modulation of vascular pathologies linked to RCAN1.4 
aberrant expression deserves further investigation.
Although in this study we have focused our attention on 
isoform PMCA4, we have shown previously that PMCA1 
(the other major PMCA isoform expressed in endothelial 
cells)13 also interacts with calcineurin in endothelial cells.15 
Thus, partial redundancy between the 2 isoforms might 
partly mask the total negative effect exerted by PMCA on 
endothelial calcineurin/NFAT signaling. Nonetheless, our 
data demonstrate that PMCA4 expression is essential for 
PMCA-mediated regulation of angiogenesis as suppression 
of PMCA4 led to a significant enhancement of angiogenesis 
in spite of background PMCA1 expression. Because targeted 
ablation of the PMCA1 gene in mice is embryolethal,36 gener-
ation of PMCA1 conditional knockout mice will be required 
to investigate its potential involvement in the regulation of 
calcineurin-dependent angiogenesis and to analyze the func-
tional consequences of deleting both isoforms in PMCA1/4 
double-knockout animals.
In conclusion, our results describe a novel role for PMCA4 
as a negative regulator of VEGF-dependent angiogenesis via 
interaction with the signaling phosphatase calcineurin.
Given the relevance of the calcineurin/NFAT signaling axis 
in the regulation of pathological angiogenesis, targeted modu-
lation of PMCA4 functionality might open new therapeutic 
avenues to promote or attenuate angiogenesis in patients expe-
riencing angiogenic disorders.
Acknowledgments
We thank Dr Bartlett and Dr McCreath for English editing and Ruth 
Alberca and Alicia Peral for technical assistance.
Sources of Funding
This work was funded by the Research Institute in Healthcare 
Science, University of Wolverhampton (to A.L. Armesilla). J.M. 
Redondo is funded by grants of the Spanish Ministry of Economy 
and Competitiveness (Ministerio de Economía y Competitividad; 
SAF 2012 34296), and the Spanish Ministry of Health (Ministerio de 
Sanidad y Consumo) Red de Investigación Cardiovascular cofunded 
by FEDER (grant RD06/0042/0022). S. Martínez-Martínez is sup-
ported by the Fundacion La Marato TV3 (122532). The Centro 
Nacional de Investigaciones Cardiovasculares (CNIC) is supported 
by the Spanish Ministry of Economy and Competitiveness and the 
Pro-CNIC Foundation. R.R. Baggott is the recipient of a PhD student-





 1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of 
angiogenesis. Nature. 2011;473:298–307.
 2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 
2000;407:249–257.
 3. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/
VEGF receptor system and its role under physiological and pathological 
conditions. Clin Sci (Lond). 2005;109:227–241.
 4. Armesilla AL, Lorenzo E, Gómez del Arco P, Martínez-Martínez S, 
Alfranca A, Redondo JM. Vascular endothelial growth factor activates 
nuclear factor of activated T cells in human endothelial cells: a role for 
tissue factor gene expression. Mol Cell Biol. 1999;19:2032–2043.
 5. Hernández GL, Volpert OV, Iñiguez MA, Lorenzo E, Martínez-Martínez 
S, Grau R, Fresno M, Redondo JM. Selective inhibition of vascular endo-
thelial growth factor-mediated angiogenesis by cyclosporin A: roles of 
 by guest on June 7, 2016http://atvb.ahajournals.org/Downloaded from 
2320  Arterioscler Thromb Vasc Biol  October 2014
the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med. 
2001;193:607–620.
 6. Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, Volpert OV. 
Nuclear factor of activated T cells balances angiogenesis activation and 
inhibition. J Exp Med. 2004;199:1513–1522.
 7. Ryeom S, Baek KH, Rioth MJ, Lynch RC, Zaslavsky A, Birsner A, Yoon 
SS, McKeon F. Targeted deletion of the calcineurin inhibitor DSCR1 sup-
presses tumor growth. Cancer Cell. 2008;13:420–431.
 8. Klee CB, Ren H, Wang X. Regulation of the calmodulin-stimulated pro-
tein phosphatase, calcineurin. J Biol Chem. 1998;273:13367–13370.
 9. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by cal-
cium, calcineurin, and NFAT. Genes Dev. 2003;17:2205–2232.
 10. Martínez-Martínez S, Redondo JM. Inhibitors of the calcineurin/NFAT 
pathway. Curr Med Chem. 2004;11:997–1007.
 11. Buch MH, Pickard A, Rodriguez A, Gillies S, Maass AH, Emerson 
M, Cartwright EJ, Williams JC, Oceandy D, Redondo JM, Neyses L, 
Armesilla AL. The sarcolemmal calcium pump inhibits the calcineurin/
nuclear factor of activated T-cell pathway via interaction with the calci-
neurin A catalytic subunit. J Biol Chem. 2005;280:29479–29487.
 12. Holton M, Yang D, Wang W, Mohamed TM, Neyses L, Armesilla AL. The 
interaction between endogenous calcineurin and the plasma membrane 
calcium-dependent ATPase is isoform specific in breast cancer cells. FEBS 
Lett. 2007;581:4115–4119.
 13. Strehler EE, Zacharias DA. Role of alternative splicing in generating iso-
form diversity among plasma membrane calcium pumps. Physiol Rev. 
2001;81:21–50.
 14. Holton ML, Wang W, Emerson M, Neyses L, Armesilla AL. Plasma mem-
brane calcium ATPase proteins as novel regulators of signal transduction 
pathways. World J Biol Chem. 2010;1:201–208.
 15. Holton M, Mohamed TM, Oceandy D, Wang W, Lamas S, Emerson M, 
Neyses L, Armesilla AL. Endothelial nitric oxide synthase activity is 
inhibited by the plasma membrane calcium ATPase in human endothelial 
cells. Cardiovasc Res. 2010;87:440–448.
 16. Wu X, Chang B, Blair NS, Sargent M, York AJ, Robbins J, Shull GE, 
Molkentin JD. Plasma membrane Ca2+-ATPase isoform 4 antagonizes 
cardiac hypertrophy in association with calcineurin inhibition in rodents. J 
Clin Invest. 2009;119:976–985.
 17. Urso K, Alfranca A, Martínez-Martínez S, Escolano A, Ortega I, Rodríguez 
A, Redondo JM. NFATc3 regulates the transcription of genes involved in 
T-cell activation and angiogenesis. Blood. 2011;118:795–803.
 18. Holmes K, Chapman E, See V, Cross MJ. VEGF stimulates RCAN1.4 
expression in endothelial cells via a pathway requiring Ca2+/calcineurin 
and protein kinase C-delta. PLoS One. 2010;5:e11435.
 19. Minami T, Yano K, Miura M, Kobayashi M, Suehiro J, Reid PC, Hamakubo 
T, Ryeom S, Aird WC, Kodama T. The Down syndrome critical region 
gene 1 short variant promoters direct vascular bed-specific gene expres-
sion during inflammation in mice. J Clin Invest. 2009;119:2257–2270.
 20. Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 
kinase mediate the mitogenic response of human endothelial cells to vas-
cular endothelial growth factor. J Cell Physiol. 1999;178:235–246.
 21. Baggott RR, Mohamed TM, Oceandy D, Holton M, Blanc MC, Roux-Soro 
SC, Brown S, Brown JE, Cartwright EJ, Wang W, Neyses L, Armesilla AL. 
Disruption of the interaction between PMCA2 and calcineurin triggers 
apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer 
cells. Carcinogenesis. 2012;33:2362–2368.
 22. Bir SC, Xiong Y, Kevil CG, Luo J. Emerging role of PKA/eNOS pathway 
in therapeutic angiogenesis for ischaemic tissue diseases. Cardiovasc Res. 
2012;95:7–18.
 23. Oliveria SF, Dell’Acqua ML, Sather WA. AKAP79/150 anchoring of cal-
cineurin controls neuronal L-type Ca2+ channel activity and nuclear sig-
naling. Neuron. 2007;55:261–275.
 24. Nieves-Cintrón M, Amberg GC, Navedo MF, Molkentin JD, Santana LF. 
The control of Ca2+ influx and NFATc3 signaling in arterial smooth muscle 
during hypertension. Proc Natl Acad Sci USA. 2008;105:15623–15628.
 25. Kim JY, Saffen D. Activation of M1 muscarinic acetylcholine receptors 
stimulates the formation of a multiprotein complex centered on TRPC6 
channels. J Biol Chem. 2005;280:32035–32047.
 26. Poteser M, Schleifer H, Lichtenegger M, Schernthaner M, Stockner T, 
Kappe CO, Glasnov TN, Romanin C, Groschner K. PKC-dependent cou-
pling of calcium permeation through transient receptor potential canonical 
3 (TRPC3) to calcineurin signaling in HL-1 myocytes. Proc Natl Acad Sci 
U S A. 2011;108:10556–10561.
 27. Makarewich CA, Correll RN, Gao H, Zhang H, Yang B, Berretta RM, 
Rizzo V, Molkentin JD, Houser SR. A caveolae-targeted L-type Ca²+ 
channel antagonist inhibits hypertrophic signaling without reducing car-
diac contractility. Circ Res. 2012;110:669–674.
 28. Fujimoto T. Calcium pump of the plasma membrane is localized in caveo-
lae. J Cell Biol. 1993;120:1147–1157.
 29. Hammes A, Oberdorf-Maass S, Rother T, et al. Overexpression of the sar-
colemmal calcium pump in the myocardium of transgenic rats. Circ Res. 
1998;83:877–888.
 30. El-Yazbi AF, Cho WJ, Schulz R, Daniel EE. Calcium extrusion by plasma 
membrane calcium pump is impaired in caveolin-1 knockout mouse small 
intestine. Eur J Pharmacol. 2008;591:80–87.
 31. Iizuka M, Abe M, Shiiba K, Sasaki I, Sato Y. Down syndrome candidate 
region 1,a downstream target of VEGF, participates in endothelial cell 
migration and angiogenesis. J Vasc Res. 2004;41:334–344.
 32. Kim HJ, Prasad V, Hyung SW, Lee ZH, Lee SW, Bhargava A, Pearce 
D, Lee Y, Kim HH. Plasma membrane calcium ATPase regulates bone 
mass by fine-tuning osteoclast differentiation and survival. J Cell Biol. 
2012;199:1145–1158.
 33. Ewart MA, Kennedy S, Macmillan D, Raja AL, Watt IM, Currie S. Altered 
vascular smooth muscle function in the ApoE knockout mouse during the 
progression of atherosclerosis. Atherosclerosis. 2014;234:154–161.
 34. Esteban V, Méndez-Barbero N, Jiménez-Borreguero LJ, Roqué M, 
Novensá L, García-Redondo AB, Salaices M, Vila L, Arbonés ML, 
Campanero MR, Redondo JM. Regulator of calcineurin 1 mediates patho-
logical vascular wall remodeling. J Exp Med. 2011;208:2125–2139.
 35. Méndez-Barbero N, Esteban V, Villahoz S, Escolano A, Urso K, Alfranca 
A, Rodríguez C, Sánchez SA, Osawa T, Andrés V, Martínez-González J, 
Minami T, Redondo JM, Campanero MR. A major role for RCAN1 in 
atherosclerosis progression. EMBO Mol Med. 2013;5:1901–1917.
 36. Prasad V, Okunade GW, Miller ML, Shull GE. Phenotypes of 
SERCA and PMCA knockout mice. Biochem Biophys Res Commun. 
2004;322:1192–1203.
Vascular endothelial growth factor has been identified as a crucial regulator of physiological and pathological angiogenesis. Among the in-
tracellular pathways triggered by vascular endothelial growth factor, activation of the calcineurin/nuclear factor of activated T cells signaling 
axis has emerged as a central mediator of angiogenic processes, highlighting the clinical potential of this route for the design of therapeutic 
interventions aimed at the treatment of neovascular-associated human diseases. Here, we have identified a critical role for the plasma 
membrane calcium ATPase 4 as a negative regulator of vascular endothelial growth factor–induced angiogenesis via downregulation of 
the calcineurin/nuclear factor of activated T cells pathway and the subsequent expression of nuclear factor of activated T cells–dependent, 
proangiogenic genes. Plasma membrane calcium ATPase 4–dependent inhibition of calcineurin signaling translates into a reduction in en-
dothelial cell motility and blood vessel formation that ultimately impairs in vivo angiogenesis by vascular endothelial growth factor. Targeted 
modulation of plasma membrane calcium ATPase 4 functionality might open novel therapeutic avenues to promote or attenuate new vessel 
formation in human diseases that occur with angiogenesis.
Significance
 by guest on June 7, 2016http://atvb.ahajournals.org/Downloaded from 
Armesilla
Arco, Sara Martínez-Martínez, Ludwig Neyses, Juan Miguel Redondo and Angel Luis 
James E. Brown, Delvac Oceandy, Elizabeth J. Cartwright, Weiguang Wang, Pablo Gómez-del
Amelia Escolano, Jorge Oller, Beatriz C. Ornes, Sathishkumar Kurusamy, Farjana B. Rowther, 
Rhiannon R. Baggott, Arantzazu Alfranca, Dolores López-Maderuelo, Tamer M.A. Mohamed,
Mediated Angiogenesis Through Interaction With Calcineurin−Factor
 Plasma Membrane Calcium ATPase Isoform 4 Inhibits Vascular Endothelial Growth
Print ISSN: 1079-5642. Online ISSN: 1524-4636 
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Greenville Avenue, Dallas, TX 75231
is published by the American Heart Association, 7272Arteriosclerosis, Thrombosis, and Vascular Biology 
doi: 10.1161/ATVBAHA.114.304363
2014;
2014;34:2310-2320; originally published online August 21,Arterioscler Thromb Vasc Biol. 
 http://atvb.ahajournals.org/content/34/10/2310
World Wide Web at: 




is onlineArteriosclerosis, Thrombosis, and Vascular Biology  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Question and Answer
Permissions and Rightspage under Services. Further information about this process is available in the
which permission is being requested is located, click Request Permissions in the middle column of the Web
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for 
 can be obtained via RightsLink, a service of theArteriosclerosis, Thrombosis, and Vascular Biologyin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on June 7, 2016http://atvb.ahajournals.org/Downloaded from 
 http://atvb.ahajournals.org/content/suppl/2014/08/21/ATVBAHA.114.304363.DC1.html




is onlineArteriosclerosis, Thrombosis, and Vascular Biology  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Question and Answer
Permissions and Rightspage under Services. Further information about this process is available in the
which permission is being requested is located, click Request Permissions in the middle column of the Web
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for 
 can be obtained via RightsLink, a service of theArteriosclerosis, Thrombosis, and Vascular Biologyin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on June 7, 2016http://atvb.ahajournals.org/Downloaded from 
SUPPLEMENTAL MATERIAL 
The Plasma Membrane Calcium ATPase isoform 4 inhibits VEGF-mediated 
angiogenesis through interaction with calcineurin 
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Amelia Escolano, Jorge Oller, Beatriz C Ornes, Sathishkumar Kurusamy, Farjana B 
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Figure I. PMCA4 significantly inhibits the activity of the calcineurin/NFAT pathway in response 
to PMA/Ionophore stimulation in endothelial cells. (A) HUVECs (3 x 105) were co-infected with 
either Ad-LacZ or Ad-PMCA4 (MOI=50) for 24 hours, and then with Ad-NFAT-Luc (MOI=25) for an 
additional 24 hours. Infected cells were serum-starved in medium containing 0.5% fetal calf serum 
and left unstimulated (-) or treated with phorbol 12 myristate 13-acetate (PMA) (20 ng/ml) and the 
calcium ionophore A23187 (1 μM) for 6 hours (PMA-Io). Mean ± S.E. of five independent experiments 
are shown. *** indicates statistically significant differences (P ≤ 0.005, according to Student’s t-test) 
when comparing PMA/Io-stimulated HUVEC infected with Ad-LacZ vs those infected with Ad-PMCA4. 
(B) MLECs (3 x 105) isolated from PMCA4 wild-type (+/+) or knock-out (-/-) animals were infected with 
Ad-NFAT-Luc (MOI=50) for 48 hours. After serum starvation in 0.5% fetal calf serum, cells were 
treated as described in (A) and luciferase activity was measured. Mean ± S.E. of five independent 
experiments are shown. ** indicates statistically significant differences (P ≤ 0.01, according to 
































































Figure II. Ectopic expression of PMCA4 decreases the levels of Cox-2 in HUVECs stimulated with 
VEGF. HUVECs were infected for 72 hours with either Ad-PMCA4 or Ad-LacZ (MOI=50) and stimulated 
with VEGF (25 ng/ml) for 4 or 2 hours for protein and RNA analysis respectively. (A) Protein lysates were 
analysed by western blot with a 1:1000 dilution of a mouse anti-Cox-1 antibody (Alexis) (WB:α-Cox1) or 
a 1:1000 dilution of a mouse anti-Cox-2 antibody (Alexis) (WB:α-Cox-2). The expression of tubulin was 
analyzed using a mouse monoclonal anti-tubulin antibody (α-Tubulin) as loading control. Histograms 
show mean ± S.E. of five independent experiments. *** indicates statistically significant differences in 
Cox-2 protein expression (P ≤ 0.005, according to Student t-test) when comparing VEGF-stimulated 
HUVEC infected with Ad-Lacz vs Ad-PMCA4.  (B) RNA levels for Cox-2 were determined by qRT-PCR 
using the 2-ΔΔCT method. Mean ± S.E. of five independent experiments is shown. * indicates statistically 
significant differences  in Cox-2 RNA levels (P ≤ 0.05, according to Student t-test) when comparing 






Figure III. Suppression of PMCA4 expression increases Cox-2 protein levels in endothelial cells 
stimulated with VEGF. (A) PMCA4 silencing enhances the expression of Cox-2 in VEGF-stimulated 
HUVECs. Western blot analyses of Cox-2 expression (α-Cox-2) in protein lysates of HUVECs 
transfected with a PMCA4-specific siRNA (si-PMCA4) or a non-targeting, control siRNA (si-NT). Cox-2 
expression was triggered by stimulating transfected cells with VEGF (25 ng/ml) for 4 hours. An image 
representative of two independent experiments is shown. (B)  Targeted ablation of PMCA4 increases 
Cox-2 protein expression in MLECs. Western blot analysis of Cox-2 expression in MLECs isolated from 
PMCA4 wild-type (+/+) or knock-out (-/-) mice. Where indicated, MLECs were stimulated with VEGF 
(50 ng/ml) for 4 hours.  An image representative of two independent experiments is shown. (A-B) The 
expression of tubulin was analyzed using a mouse monoclonal anti-tubulin antibody (α-Tubulin) as 
loading control.  
Figure IV. Disruption of the PMCA4/calcineurin interaction promotes upregulation of RCAN1.4 expression 
by a cyclosporine A-sensitive mechanism. (A) Ectopic expression of the region 428-651 of PMCA4 disrupts 
the interaction PMCA/calcineurin in the plasma membrane of endothelial cells. HUVECs were infected with Ad-
LacZ (control) or Ad-ID4 at a MOI=150 for 72 hours. Membrane-associated and whole-cell total proteins were 
isolated from the infected cells and analysed by western blot with a 1:1000 dilution of an anti-calcineurin A 
antibody (α-Calcineurin A) or a 1:500 dilution of the JA3 anti-PMCA4 specific antibody (α-PMCA4) to determine 
the level of calcineurin or PMCA4 associated to the plasma membrane, and the total expression of calcineurin or 
PMCA4 respectively.  Expression of 3xFlag-PMCA4(428-651) was examined by western blot in total extracts of 
infected cells using a 1:2000 dilution of the M2 anti-Flag monoclonal antibody (Sigma) (α-Flag). The expression of 
tubulin was analyzed using a mouse monoclonal anti-tubulin antibody (α-Tubulin) as loading control. (B) HUVECs 
were infected with Ad-LacZ or Ad-ID4 at MOI=150 for 72 hours and expression of RCAN1.4 was induced by 
stimulation with VEGF (25 ng/ml) for 4 hours. Where indicated, cells were pre-incubated with the calcineurin 
inhibitor cyclosporine A (CsA) (200 ng/ml) for two hours prior to VEGF stimulation. RCAN1.4 expression was 
examined by western blot using a rabbit anti-DSCR1 antibody (α-RCAN1.4). The expression of tubulin was 
analyzed using a mouse monoclonal anti-tubulin antibody (α-Tubulin) as loading control. Histogram shows mean 
± S.E of four independent experiments. *** indicates statistically significant differences in the levels of RCAN1.4 
protein expression (P ≤ 0.005, according to Student t-test) when comparing protein extracts isolated from VEGF-










Figure V. Disruption of the interaction PMCA/calcineurin increases the basal 
expression of RCAN1.4 in endothelial cells. Western blot showing results of RCAN1.4 
expression levels in Ad-LacZ or Ad-ID4 infected HUVECs, after short or long exposure of the 
autoradiography film to the western blot membrane during ECL detection. The image 
obtained after short exposure of the film (α-RCAN1.4 upper panel) shows the increase in 
RCAN1.4 expression observed in VEGF-stimulated HUVECs after disruption of the 
PMCA/calcineurin interaction by infection with Ad-ID4. Given the high level of RCAN1.4 
expression triggered by VEGF stimulation, long exposure of the film (α-RCAN1.4 lower 
panel) masked the differences in RCAN1.4 expression as the system became saturated, 
however, long exposure of the film revealed that basal RCAN1.4 expression in unstimulated 
cells is augmented by disruption of the PMCA4/calcineurin interaction. This result is in 
agreement with the increase in RCAN1.4 basal expression observed in unstimulated 
PMCA4 knockout MLEC (Fig 2E).    
Figure VI. Enhanced endothelial cell migration in PMCA4 (-/-) MLECs is mediated by Cox-2. Cox-
2 inhibition strongly abrogates the increase in migration observed in PMCA4 knockout cells. PMCA4 (-
/-) MLEC cells were pre-treated with the Cox-2 specific inhibitor Etoricoxib (15 μM) (or DMSO vehicle 
as a control) for 1 hour before incubation for 24 hours in MLEC medium containing VEGF (50 ng/ml). 
Images were taken at time zero and after 24 hours incubation. The migrated area was calculated by 
subtracting the value of the non-migrated area to the area of the wound at time zero. The migrated area 
is expressed as a percentage of the total area at time zero. Histogram represents mean ± S.E. of four 
independent experiments. *** indicates statistically significant differences (P ≤ 0.005, according to 
Student’s t-test) when comparing VEGF-induced migration of PMCA4 knockout MLECs after pre-




Figure VII. VEGF stimulation induces a transient increase of PMCA4 protein levels in HUVEC. 
Protein lysates from HUVECs stimulated with VEGF (25 ng/ml) for the indicated times were analysed 
by western blot with an anti-PMCA4 specific antibody (α-PMCA4) to determine the expression levels 
of PMCA4. Histogram shows data as mean ± S. E. of three independent experiments. Differences 
between results were evaluated by one-way ANOVA and Newman-Keuls post hoc test. * and ## 
indicate statistically significant differences P ≤ 0.05 and P ≤ 0.01, respectively when comparing 
PMCA4 expression levels at 4 or 6 hours vs expression in non-stimulated cells (0 h). 
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Materials and Methods 
 
Cells and cell culture 
Human umbilical vein endothelial cells (HUVECs) were purchased from PromoCell or 
TCS Cellworks, and were cultured in 0.1% gelatin-coated tissue culture flasks 
containing Endothelial Cell Growth Medium (ECGM; PromoCell) supplemented with 
ECGM-supplement mix (PromoCell) and 1% penicillin/streptomycin. HUVECs were 
used at passages 5-8.  
Mouse lung endothelial cells (MLECs) were purified from wild-type or PMCA4 null 
mice. Purification and culture of MLECs was as described.1 Mice deficient in PMCA4 
have been previously characterized.2 
When indicated HUVEC or MLEC were stimulated with VEGF at 25 or 50 ng/ml, 
respectively. RCAN1.4 and Cox-2 expression levels in endothelial cells were 
determined after 2 hours (for RNA) or 4 hours (for protein expression) of stimulation 
with VEGF, as these time points have been previously reported to show optimum 
expression levels of RNA and protein for these genes.3,4 Assays of endothelial cell 
migration or tube formation in matrigel, which require activation of several cellular 




Generation of adenoviruses Ad-LacZ and Ad-PMCA4 have been previously described.6 
Ad-NFAT-Luc is a replication-deficient adenovirus harbouring an NFAT-dependent 
luciferase-based reporter system. To generate Ad-NFAT-Luc, the plasmid pNFAT-TA-
Luc (Clontech) was digested with Kpn I and Sal I. The fragment containing the NFAT-
dependent luciferase reporter system (three tandem copies of the NFAT consensus 
sequence, the TATA box of the herpes simplex virus thymidine kinase promoter and 
the firefly luciferase reporter gene) was purified and sub-cloned into the Kpn I and Sal I 
sites of the pENTR11 shuttle vector (Invitrogen). The resulting plasmid was subjected 
to recombination with the pAd-DEST vector (Invitrogen) using the LR Clonase II 
enzyme system following the protocol recommended by the manufacturer. 
Adenovirus Ad-ID4 encodes a 3xFlag-tagged version of the region encompassing 
amino acids 428 to 651 of human PMCA4b (corresponding to the domain of PMCA4b 
implicated in the interaction with calcineurin A). To generate Ad-ID4,  the region of pF-
PMCA4b(428-651)7 that encodes three copies of the Flag epitope fused to the domain 
428-651 of PMCA4b was amplified by PCR using plasmid pF-PMCA4b(428-651) as a 
template and oligonucleotides BamHI-PMCA4b sense (5'-
TCTTCgCggATCCTTAgTgAACCgTCAgAATTAACC-3') and XhoI-PMCA4b antisense 
(5'-TCTTCCgCTCgAgTCAAgAgggCTCTgTgTCATCgAA-3'). The amplified fragment 
was cloned into the BamHI and XhoI sites of the pENTR11 shuttle vector (Invitrogen). 
The resulting plasmid was subjected to recombination with the pAd-DEST vector 
(Invitrogen) using the LR Clonase II enzyme system following the protocol 
recommended by the manufacturer. 
Adenovirus particles were generated in HEK293 cells as previously described.6 
 
Luciferase reporter assay 
HUVECs or MLECs infected with the corresponding adenovirus were serum-starved in 
basal medium containing 0.5% fetal calf serum for 16 hours and subsequently 
stimulated as indicated for 6 hours. 
Luciferase activity was determined as described.8  
 
Western blot 
HUVECs or MLECs infected with the corresponding adenovirus for 72 hours were 
serum-starved in basal medium containing 0.5% fetal calf serum for 16 hours and 
stimulated as indicated. Western blot procedures were as described.9 
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Western blot membranes were incubated with a 1:500 dilution of the JA3 mouse 
monoclonal anti-PMCA4 antibody (Santa Cruz) or a 1:10000 dilution of a rabbit anti-
PMCA4 antibody (Swant) (for PMCA4 detection), a 1:10000 dilution of a rabbit anti-
PMCA1 antibody (Swant) (for PMCA1 detection), a 1:1000 dilution of a rabbit anti-
DSCR1 antibody (Sigma) (for RCAN1.4 detection), a 1:2500 dilution of a mouse 
monoclonal anti-tubulin antibody (Sigma) (for tubulin detection), a 1:1000 dilution of a 
rabbit anti-phospho-Erk1/2 (Thr202/Tyr204) antibody (Cell Signaling) (for detection of 
phosphorylated (activated) Erk1/2) or a 1:1000 dilution of a rabbit anti-Erk1/2 antibody 
(Cell Signaling) (for detection of total Erk1/2). Primary antibodies were detected by 
incubation in either a 1:7500 dilution of peroxidase-conjugated sheep anti-mouse 
immunoglobuilin antibody (Sigma) or 1:7500 dilution of peroxidase-conjugated donkey 
anti-rabbit immunoglobulin antibody (GE Healthcare) depending of the origin of the 
primary antibody. All antibody dilutions were carried out in TBS-T. 
 
Immunoprecipitation 
Protein lysates from infected cells were immunoprecipitated using the anti-pan PMCA 
monoclonal antibody 5F10 as previously described.10 
Immunoprecipitated proteins were analyzed by western blot. 
 
Polymerase chain reaction  
RNA from HUVECs or MLECs was extracted using the “Total RNA purification kit” 
(Norgen) and cDNA synthesis was performed with 0.5 µg of total RNA using the “High 
capacity cDNA reverse transcription kit” (Applied Biosystems).  
Presence of RNA encoding for PMCA1 and PMCA4 in MLEC cells was determined by 
semi-quantitative PCR performed on retro-transcribed samples using oligonucleotides 
mousePMCA1sense (5'-TCTggCTACggAACCACCCA-3') and mouse PMCA1anti (5'-
AAAggCTTCCCgCCAAACTg-3') or mousePMCA4sense (5'- 
CAAgCCTCTgATCTCCCgCA-3') and mousePMCA4anti (5'- 
CCACTgCTCCATggTCAggC-3'). Amplification of the housekeeping gene Hprt1 was 
performed with oligonucleotides mouseHprt1sense (5'- CCTAAgATgATCgCAAgTTg-3') 
and mouseHprt1anti (5'- CCACAgggACTAgAACACCTgCTAA-3') to verify equal RNA 
levels in both samples. PCR reactions were analyzed by agarose gel electrophoresis.  
cDNA samples resulting from retro-transcription reactions with RNA isolated from 
HUVEC cells were subjected to SYBR green real-time PCR using oligonucleotides 
RCAN1.4forward (5'-CTCACTAggggCTTgACTgC-3') and RCAN1.4reverse (5'-
CAggCAATCAgggAgCTAAA-3') for amplification of human RCAN1.4, or COX-2forward 
(5'-gAAgAAAgTTCATCCCTgATCCC-3') and COX-2reverse (5'-
CTgggCAAAgAATgCAAACA-3') for amplification of human COX-2, in a Stratagene 
MX3000P thermal cycler using the following conditions, 95˚C for 10 minutes, followed 
by 40 cycles of 95˚C for 15 seconds and 60˚C for 1 minute. The Ct value was 
normalized using the Ct values for the housekeeping genes Ubiquitin and YwHaz. 
Analysis of RT-qPCR data was carried out using the comparative 2-ΔΔCT method. 
 
siRNA gene knock-down 
siRNA-mediated knock-down was performed using “ON-TARGET-plus SMART pool 
human ATP2B4” (Thermo Scientific) targeting PMCA4, or “ON-TARGET-plus non-
targeting pool control duplexes” (Thermo Scientific). HUVECs (0.5 x 106) were 
transfected with 30 pmoles of siRNAs by electroporation using an AMAXA HUVEC 
nucleofector kit (AMAXA). 
 
Wound healing migration assay 
Cell migration of HUVECs (infected with the corresponding adenovirus) and MLECs 
was performed with the “CytoselectTM 24-well wound healing assay kit” (Cell Biolabs). 
Images were recorded with a Nikon DSFi1 digital camera mounted on a Nikon 
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ECLIPSE TS100 microscope at 4x magnification. The cell-free area was calculated 
with ImageJ software.  
 
Matrigel tube formation assay 
HUVECs infected with adenovirus or transfected with siRNA, were seeded onto Geltrex 
Reduced Growth-Factor Matrix (Invitrogen) in Medium 200 without phenol red, 
supplemented with 2% fetal calf serum (containing 50 ng/ml VEGF where indicated) in 
96-well tissue culture plates at a density of 3 x 104 cells/well. Tube formation was 
quantified after incubation at 37º for 24 hours. Tube formation was recorded with a 
Nikon DSFi1 digital camera mounted on a Nikon ECLIPSE TS100 microscope at 4x 
magnification. 
 
In vivo Matrigel plug assay 
The use of adenovirus embedded in matrigel plugs is a well-established method for the 
delivery of exogenous proteins into endothelial cells that vascularize the plug.11-13 
Angiogenesis was quantified in vivo by Matrigel plug assays as described4, with the 
following modifications: for analysis of the effect of PMCA4 overexpression, the 
Matrigel mixture contained Growth-Factor Reduced Matrigel (BD Bioscience) VEGF 
(500 ng/ml), heparin (376 µg/ml) and 2 x 109 p.f.u. of the corresponding adenovirus 
(Ad-LacZ or Ad-PMCA4). The Matrigel mixture was implanted subcutaneously in 4-
week-old anesthetized C57BL/6 mice, and 7 days later implants were collected and 
analyzed.  For angiogenesis measurements in the absence of PMCA4, no adenovirus 
was included in the implant mixture, and the experiments were performed in 4-week-
old PMCA4 knock-out mice or their corresponding wild-type littermates.  
After seven days, mice were euthanized and Matrigel plugs were collected and divided 
into two portions for measurement of hemoglobin content and blood vessel number as 
described.4 
Experiments were performed in accordance with the guidelines of the EU on animal 
care, and approved by the Animal Care and Ethics committee at Centro Nacional de 
Investigaciones Cardiovasculares.   
 
Murine hindlimb ischaemia 
Unilateral hindlimb ischaemia was induced by double ligation, and subsequent 
removal, of the left femoral artery in 12-week-old PMCA4 wild type or knockout mice 
under 2% isoflurane anesthesia. Blood flow was measured in anesthetized animals at 5 
and 14 days after surgery using a Laser Doppler Perfusion Imager System (Moor 
Instruments). The ischemic to non-ischemic foot blood flow ratio was used as an index 
of blood flow recovery. 
Experiments were performed in accordance with the guidelines of the EU on animal 
care, and approved by the Animal Care and Ethics committee at Centro Nacional de 
Investigaciones Cardiovasculares.   
 
MTT assay 
HUVECs infected with Ad-LacZ or Ad-PMCA4 were seeded at a density of 2 x 104 
cells/well in ECGM with supplement mixture in 96-well tissue culture plates (without 
gelatin pre-coating). The MTT assay was performed, as described14, the morning after 
plating the cells (time=0) and then after 3 and 6 days of incubation in ECGM with 
supplement mixture containing VEGF (25 ng/ml).  
 
Statistical analysis 
Results are expressed as Mean ± S.E. The Student’s t-test was used to determine the 
significance of differences between two groups. In supplementary figure Fig VII, 
comparison among groups was determined by one-way ANOVA with post hoc 
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